Research To Practice

User Login | Create Account | Contact Us

  • Facebook
  • Instagram
  • X
  • LinkedIn
  • TikTok
  • Home
  • Browse By Tumor Type
  • Upcoming Events
  • About Us
  • Subscribe
  • CME Post-Tests
Home
We've determined that you are accessing this site using a mobile device. Please select which version of the site you would like to browse.
 

Management of Myelofibrosis

Email from the Editor

Overview Matrix

Initial Tx for 65 yo, int-2, sympt MF, baseline anemia? High-risk MF, anemia develops on Rux: Adjust dose?

Usual Tx (+/- corticosteroids) for pts w/ asymptomatic MF but w/ anemia?

Rux dose for 65 yo, symptomatic high-risk MF, platelet count 35K/µL? Platelet count 70K/µL?

Change Tx for spleen enlargement after response on Rux? Taper/stop Rux on progression after 1 y of response?

Additional Commentary:

Cross-resistance between Rux and other JAK2 inhibitors?

Is hydroxyurea considered leukemogenic?

How common is the occurrence of hydroxyurea-related leg ulcers?

Role of iron chelation for pts with MF and frequent transfusions?

CME Information

Additional Commentary


Additional Faculty Comments:

  • Cross-resistance between Rux and other JAK2 inhibitors?
  • Is hydroxyurea considered leukemogenic?
  • How common is the occurrence of hydroxyurea-related leg ulcers?
  • Role of iron chelation for pts with MF and frequent transfusions?
  • Subscribe to RTP Programs
  • Podcast
  • Download Mobile App
  • Privacy Policy
  • Terms of Use

Copyright © 2025 Research To Practice. All Rights Reserved.